Personalized Antiplatelet Therapy to Prevent Recurrent Cardiovascular Events in After Ischemic Stroke
Condition(s) studied
Investigational drug(s) / intervention(s)
Acetylsalicylic acid (ASA)/aspirin 100 mg daily: Aspirin acts as an irreversible inhibitor of COX-1/-2 enzymes, decreasing prostaglandin precursors formation and inhibiting platelet aggregation. It is the most prescribed medication for cardio-cerebrovascular diseases prevention, as this has been the first antiplatelet with demonstrated effectiveness and safety (Rothlisberger and Ovbiagele, 2015).
Clopidogrel 75 mg daily: Clopidogrel works by irreversibly blocking the P2Y12 component of ADP receptors on platelets preventing the activation of GPIIb/IIIa receptor complexes (Rothlisberger and Ovbiagele, 2015).
Ticlopidine 250 mg twice daily: Ticlopidine has a mechanism of action similar to Clopidogrel, as it works by irreversibly blocking the P2Y12 component of ADP receptors on platelets preventing the activation of GPIIb/IIIa receptor complexes. However it takes longer time to reach the maximal effect (Rothlisberger and Ovbiagele, 2015).
Study summary
The TAILOR study aims to determine whether personalized antiplatelet therapy can reduce the risk of recurrent major cardiovascular events in patients who have experienced (a non-cardioembolic ischemic stroke).
Antiplatelet medications, such as aspirin and clopidogrel, are commonly prescribed to prevent stroke recurrence. However, some patients do not respond adequately to these medications and may remain at increased risk of further cardiovascular events.
The study will compare two approaches to antiplatelet therapy: standard care, in which medications are prescribed according to current clinical practice, and personalized care (tailored care), in which treatment is adjusted based on a blood test measuring how effectively the medication inhibits platelet activity.
Participants will be randomly assigned to one of these two treatment strategies and followed for 12 months.
The main hypothesis is that tailoring antiplatelet therapy according to individual platelet response will be more effective than standard care in preventing recurrent ischemic stroke, myocardial infarction, or cardiovascular death. The study will also explore potential differences in treatment response between women and men.
Eligibility
Primary outcome measure(s)
- Major Cardiovascular Event at 12 months — From randomization to 12 months
Time to the first occurrence of a composite event comprising ischemic stroke, myocardial infarction, or cardiovascular death within 3 months after randomization. The outcome will be assessed as time to first event (days) and cumulative incidence (percentage of participants experiencing at least one event).
Trial sites (3)
| Facility | City | Region | Status |
|---|---|---|---|
| IRCCS Istituto delle Scienze Neurologiche di Bologna - Azienda USL di Bologna | Bologna | BO | |
| Ospedale Civile di Baggiovara | Modena | MO | |
| Ospedale Bufalini - AUSL della Romagna | Cesena | Italy |
More Azienda Usl di Bologna trials in Italy
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07943026 on ClinicalTrials.gov ↗ ← All trials in Italy